An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 276-278

  Gantt, Soren ^a,b   Huang, Meei Li ^b,c   Magaret, Amalia ^b,c   Bunts, Lisa ^c   Selke, Stacy ^b,c   Wald, Anna ^b,c   Rosenthal, Philip J ^d   Dorsey, Grant ^d   Casper, Corey ^b,c  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral; Artesunate; Cytomegalovirus; Malaria; Treatment

Indexed keywords

AMODIAQUINE; ARTESUNATE; PYRIMETHAMINE; SULFADOXINE; VIRUS DNA;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRIED BLOOD SPOT TESTING; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; INFANT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE DRUG DOSE; UGANDA;

EID: 84881553857     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.008     Document Type: Article

References (19)

1. Mocarski E.S., Shenk T., Pass R.F. Cytomegaovirus. Field's virology 2007, Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R. Lamb, M. Martin, B. Roizman (Eds.).
2. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71:154-163.
3. Kaptein S.J., Efferth T., Leis M., Rechter S., Auerochs S., Kalmer M., et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006, 69:60-69.
4. Efferth T., Marschall M., Wang X., Huong S.M., Hauber I., Olbrich A., et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 2002, 80:233-242.
5. Chou S., Marousek G., Auerochs S., Stamminger T., Milbradt J., Marschall M. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res 2011, 92:364-368.
6. Schnepf N., Corvo J., Pors M.J., Mazeron M.C. Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. Antiviral Res 2011, 89:186-188.
7. Efferth T., Romero M.R., Wolf D.G., Stamminger T., Marin J.J., Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008, 47:804-811.
8. Zwang J., Dorsey G., Djimde A., Karema C., Martensson A., Ndiaye J.L., et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012, 11:260.
9. Shapira M.Y., Resnick I.B., Chou S., Neumann A.U., Lurain N.S., Stamminger T., et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46:1455-1457.
10. Lau P.K., Woods M.L., Ratanjee S.K., John G.T. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011, 52:279.
11. Wolf D.G., Shimoni A., Resnick I.B., Stamminger T., Neumann A.U., Chou S., et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011, 90:183-186.
12. Walter S., Atkinson C., Sharland M., Rice P., Raglan E., Emery V.C., et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed 2008, 93:F280-F285.
13. Staedke S.G., Mpimbaza A., Kamya M.R., Nzarubara B.K., Dorsey G., Rosenthal P.J. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 2004, 364:1950-1957.
14. Dorsey G., Staedke S., Clark T.D., Njama-Meya D., Nzarubara B., Maiteki-Sebuguzi C., et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007, 297:2210-2219.
15. Boeckh M., Huang M., Ferrenberg J., Stevens-Ayers T., Stensland L., Nichols W.G., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-1148.
16. Limaye A.P., Hayes T.K., Huang M.L., Magaret A., Boeckh M., Jerome K.R. Quantitation of cytomegalovirus (CMV) DNA load in dried blood spots (DBS) correlates well with plasma viral load. J Clin Microbiol 2013.
17. Asberg A., Humar A., Rollag H., Jardine A.G., Mouas H., Pescovitz M.D., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7:2106-2113.
18. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190:177-182.
19. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., Burroughs A.K., Sweny P., Griffiths P.D., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191:89-92.